Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,001–1,100 of 2,162
Challenges and opportunities for monoclonal antibody therapy in veterinary oncology
Beirão, B. C. B., Raposo, T. P., Jain, S., Hupp, T. R., & Argyle, D. J. (2016) · The Veterinary Journal · doi:10.1016/j.tvjl.2016.11.005 · Cited by 24
The Evolving Landscape of Cancer Therapeutics
Khan, M. M., & Spicer, J. F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_312 · Cited by 17
Lu, X., Wang, J., Chen, X., Jiang, Y., & Pan, Z. K. (2020) · Scientific Reports · doi:10.1038/s41598-019-56899-6 · Cited by 17
Godbersen, C., Coupet, T. A., Grada, Z., Zhang, S. C., & Sentman, C. L. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1901401 · Cited by 20
A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy
Liang, J., Zhang, H., Huang, Y., Fan, L., Li, F., Li, M., Yan, Y., Zhang, J., Li, Z., & Yang, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s330637 · Cited by 20
“Unfortunately, the CD28 superagonist, TGN1412, was suspended due to severe CRS after infusion.(24) It remains unclear whether tumor-targeted CD28 activation can maintain its T cell co-stimulation ability and reduce off-tumor adverse effects.”
BackgroundHitomi, Y., Aiba, Y., Ueno, K., Nishida, N., Kawai, Y., Kawashima, M., Tsuiji, M., Iwabuchi, C., Takada, S., Miyake, N., et al. (2022) · Human Genomics · doi:10.1186/s40246-022-00419-7 · Cited by 18
“Although a CD28 super-agonist (theralizumab TGN1412) caused cytokine storm in healthy volunteers in a first-in-human study [65], a clinical trial of a novel type of CD28 super-agonist (TAB08) has been performed [66].”
BackgroundGonsette, R. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1103 · Cited by 18
“TGN-1412 fully activates T cells even in the absence of T-cell receptor stimulation and this ‘mitogenic’ monoclonal antibody led to indiscriminate attacks of normal tissues and catastrophic adverse reactions in a Phase I trial [114].”
BackgroundSA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines
Sharma, R. K., Yolcu, E. S., & Shirwan, H. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.880340 · Cited by 19
“For example, a single intravenous dose of an anti-CD28 mAb in six healthy volunteers resulted in life-threatening toxicity due to systemic inflammatory responses in a Phase I clinical trial [69].”
BackgroundDo we have memory of danger as well as antigen?
Noble, A. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.02.001 · Cited by 18
ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
Cavagnaro, J. A., & Sims, J. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-5950-7_10 · Cited by 19
Kenter, M. J. H., & Cohen, A. F. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12605 · Cited by 17
First-in-Human Clinical Trials — What We Can Learn from Tragic Failures
Bonini, S., & Rasi, G. (2016) · New England Journal of Medicine · doi:10.1056/nejme1609006 · Cited by 17
Crescioli, S., Jatiani, S., & Moise, L. (2025) · mAbs · doi:10.1080/19420862.2025.2453515 · Cited by 18
PRO: Regulatory T Cells Are Protective in Ischemic Stroke
Hu, X., Li, P., & Chen, J. (2013) · Stroke · doi:10.1161/strokeaha.113.001267 · Cited by 17
Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders
Vanhove, B., Poirier, N., Fakhouri, F., Laurent, L., Hart, B. A. ‘., Papotto, P. H., Rizzo, L. V., Zaitsu, M., Issa, F., Wood, K. J., et al. (2017) · Antibodies · doi:10.3390/antib6040019 · Cited by 17
““Superagonistic” anti-CD28 antibodies (such as the TGN1412 antibody [22]) bind to the laterally exposed C”D loop of CD28 and induce a non-physiological engagement of CD28 resulting in polyclonal T cell activation and cytokine release even in the absence of TCR stimulation [23].”
BackgroundBelatacept/CTLA4Ig: an update and critical appraisal of preclinical and clinical results
Schwarz, C. C., Mahr, B., Muckenhuber, M., & Wekerle, T. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1485489 · Cited by 17
“Moreover, the catastrophic outcome of a phase I trial investigating a deliberately superagonistic antiCD28 monoclonal antibody (TGN1412) cautioned against the use of CD28 as target antigen [108].”
BackgroundDavid, C. A. W., Barrow, M., Murray, P. A., Rosseinsky, M. J., Owen, A., & Liptrott, N. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165610 · Cited by 20
“1 mg dose of theralizumab per kilogram of body weight [4], 500-times smaller than that deemed safe by preclinical animal studies [5].”
BackgroundMethodCurrent Immunotherapy Approaches in Non-Hodgkin Lymphomas
Pytlík, R., Polgárová, K., Karolová, J., & Klener, P. (2020) · Vaccines · doi:10.3390/vaccines8040708 · Cited by 24
“Upon contact with the tumor cells, T-cells secrete inflammatory cytokines such as TNF-α and IFN-γ, which in turn stimulate secretion of IL-1, IL-6, inducible nitric oxide synthase (iNOS) and other cytokines by monocytes and macrophages.”
BackgroundThoreau, F., & Chudasama, V. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00082a · Cited by 18
Targeting immunoregulation for cardiac regeneration
Li, R., Xiang, C., Li, Y., & Nie, Y. (2023) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2023.02.003 · Cited by 18
Matsumoto, M., Polli, J. R., Swaminathan, S. K., Datta, K., Kamperschroer, C., Fortin, M. C., Salian‐Mehta, S., Dave, R. A., Yang, Z., Arora, P., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3316 · Cited by 19
“6 7-9 The MABEL calculation considers various pharmacokinetic and pharmacodynamic (PK/PD) data, such as target binding, receptor occupancy (RO), exposure-response analyses, and exposures at pharmacological doses in relevant animal species.”
Immune‐related adverse events of antibody‐based biological medicines in cancer therapy
Rajagopal, D., MacLeod, E., Corogeanu, D., & Vessillier, S. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.18470 · Cited by 22
“155 Further studies, to understand the reasons behind the TGN1412 clinical trial failure, revealed that CD28 is highly expressed in human CD4 + effector memory T-cells, but not in cynomolgus or rhesus macaques employed in preclinical testing.”
BackgroundUno, Y., & Osada, N. (2011) · BMC Evolutionary Biology · doi:10.1186/1471-2148-11-283 · Cited by 17
Ballow, M. C., Akdiş, C. A., Casale, T. B., Wardlaw, A. J., Wenzel, S. E., Ballas, Z. K., & Lötvall, J. O. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.04.046 · Cited by 17
“However, when 6 healthy young male volunteers received this mAb, within 90 minutes, all had a systemic inflammatory process characterized by the release of proinflammatory cytokines and a constellation of systems consistent with a cytokine storm.(127) This experience underscores the importance of being very careful in…”
BackgroundBispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Dicato, M. A., & Diederich, M. F. (2015) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201016666150505124037 · Cited by 17
Review: Innovative monoclonal antibody therapies in multiple sclerosis
Linker, R. A., & Kieseier, B. C. (2008) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285608093945 · Cited by 18
Fletcher, E. A. K., Eltahir, M., Lindqvist, F., Rieth, J., Törnqvist, G., Leja-Jarblad, J., & Mangsbo, S. M. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.10.021 · Cited by 17
“However, these types of assays failed to predict the TGN1412 clinical trial responses, where six healthy volunteers were infused with the antiCD28 antibody, which led to anaphylactic responses and multi-organ failure [5].”
BackgroundSadewasser, A., Dietzel, E., Michel, S., Klüver, M., Helfer, M., Thelemann, T., Klar, R., Eickmann, M., Becker, S., & Jaschinski, F. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.04.018 · Cited by 17
Copsel, S. N., Wolf, D., Komanduri, K. V., & Levy, R. B. (2019) · Haematologica · doi:10.3324/haematol.2018.198838 · Cited by 19
Carratalá, J. V., Cano‐Garrido, O., Sánchez, J. M., Membrado, C., Pérez, E., Conchillo‐Solé, O., Daura, X., Sánchez‐Chardi, A., Villaverde, A., Arís, A., et al. (2020) · New Biotechnology · doi:10.1016/j.nbt.2020.02.001 · Cited by 19
Watson, G. A., Doi, J., Hansen, A. R., & Spreafico, A. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14355 · Cited by 20
“igently scrutinized, as evidenced by the events observed with an immunomodulatory anti-CD28 superagonist mAb (TGN1412), which resulted in six patients requiring admission to intensive care for lifethreatening cytokine-release syndrome (CRS).(42) One approach accepted and recommended by both the US Food and Drug Admini…”
BackgroundYang, J., Lickliter, J. D., Hillson, J., Means, G., Sanderson, R. J., Carley, K., Tercero, A., Manjarrez, K. L., Wiley, J. R., & Peng, S. L. (2021) · Clinical and Translational Science · doi:10.1111/cts.12983 · Cited by 19
Diabetes and susceptibility to infections: Implication for COVID‐19
van Niekerk, G., van der Merwe, M., & Engelbrecht, A. (2021) · Immunology · doi:10.1111/imm.13383 · Cited by 18
CD28 and ICOS play complementary non-overlapping roles in the development of Th2 immunity in vivo
Shilling, R. A., Clay, B. S., Tesciuba, A. G., Berry, E. L., Lu, T. Y., Moore, T. V., Bandukwala, H. S., Tong, J., Weinstock, J. V., Flavell, R. A., et al. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.06.013 · Cited by 24
Medina, M. Á., Couturier, J. P., Feske, M. L., Mahne, A. E., Turner, M. A., Yu, X., Kozinetz, C. A., Orozco, A. F., Hutchison, A. T., Savidge, T., et al. (2012) · Journal of Leukocyte Biology · doi:10.1189/jlb.0511264 · Cited by 20
Immunosuppression Armamentarium in 2010: Mechanistic and Clinical Considerations
Urschel, S., Altamirano‐Diaz, L., & West, L. J. (2010) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.01.018 · Cited by 17
Therapeutic advances in rheumatology with the use of recombinant proteins
Rothe, A., Power, B. E., & Hudson, P. J. (2008) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0909 · Cited by 19
“In 2006, TGN1412, manufactured by TeGenero Immuno Therapeutics, an activating anti-CD28 antibody, came into public prominence when clinical trials led to multi-organ failure and cytokine storm after its first administration in humans”
BackgroundDrug development in inflammatory bowel disease: The role of the FDA
Lahiff, C. J., Kane, S. V., & Moss, A. C. (2011) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21712 · Cited by 17
“Phase I studies in healthy human volunteers caused multiorgan failure in four subjects within hours of receiving the drug by infusion, despite the fact that preclinical testing in macaques caused nothing but mild lymphadenopathy.(16) Preclinical studies of immunosuppressive effects are limited to conventional measurem…”
BackgroundMénard, J. (2006) · Journal of Hypertension · doi:10.1097/hjh.0b013e328012981b · Cited by 17
Panoskaltsis, N., McCarthy, N. E., Stagg, A. J., Mummery, C. J., Husni, M., Arebi, N., Greenstein, D., Price, C. L., Al-Hassi, H. O., Koutinas, M., et al. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02725-2 · Cited by 16
Self-citationBorn to be wild: utilizing natural microbiota for reliable biomedical research
Bruno, P., Schüler, T., & Rosshart, S. P. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.11.013 · Cited by 20
Holay, N., Yadav, R., Ahn, S. J., Kasiewicz, M. J., Polovina, A., Rolig, A. S., Staebler, T., Becklund, B. R., Simons, N. D., Koguchi, Y., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011524 · Cited by 16
The significance of non-human primates as preclinical models of human arthritic disease
Vierboom, M., Breedveld, E., Kondova, I. I., & Hart, B. A. ‘. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.3.299 · Cited by 15
Triggers, Timescales, and Treatments for Cytokine-Mediated Tissue Damage
McBride, D. A., Kerr, M., Dorn, N. C., Ogbonna, D. A., Santos, E., & Shah, N. J. (2020) · EMJ Innovation · doi:10.33590/emjinnov/20-00203 · Cited by 24
Rengelshausen, J., Breithaupt-Groegler, K., Donath, F., Erb‐Zohar, K., Hardman, T. C., Mikus, G., Plassmann, S., Wensing, G., & Sourgens, H. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00257-0 · Cited by 15
“While more than 3000 FIH trials have been conducted in the European Union (EU) [2] over the last 14 years, there have been two incidents where exposure to IMP has resulted in tragic consequences: the serious systemic inflammatory responses (cytokine storm) following the first administration of TGN1412 in 2006 [3] and…”
BackgroundA vaccine to prevent initial loss of cognition and eventual Alzheimer's disease in elderly persons
Fessel, J. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12126 · Cited by 17
Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma
Sakamoto, Y., Ishida, T., Masaki, A., Takeshita, M., Iwasaki, H., Yonekura, K., Tashiro, Y., Ito, A., Kusumoto, S., Iida, S., et al. (2021) · Cancer Science · doi:10.1111/cas.15191 · Cited by 17
Preclinical Safety Evaluation of Monoclonal Antibodies
Lynch, C. M., & Grewal, I. S. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_2 · Cited by 17
Co-signals in organ transplantation
Dürrbach, A., François, H., Jacquet, A., Beaudreuil, S., & Charpentier, B. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e32833c1369 · Cited by 16
Descotes, J. (2012) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2012.05.001 · Cited by 16
“, 2007), and the so-called cytokine storm in healthy volunteers enrolled in a phase I clinical trial of the monoclonal antibody TGN1412 (Suntharalingam et al., 2006).”
BackgroundInfluentialIssues, challenges, and opportunities in model-based drug development for monoclonal antibodies
Hu, L., & Hansen, R. J. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23504 · Cited by 17
Brunn, N. D., Mauze, S., Gu, D., Wiswell, D., Ueda, R., Hodges, D., Beebe, A. M., Zhang, S., & Escandón, E. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229864 · Cited by 16
“While modulation of costimulatory pathways have shown great preclinical potential as immunotherapies, immunerelated adverse events ranging from hyper-costimulation to cytokine dysregulation and immunogenicity have been observed (Chirino et al., 2004; Reuben et al., 2006; Suntharalingam et al., 2006; Brennan et al., 20…”
BackgroundVirus infection drives IL-2 antibody complexes into pro-inflammatory agonists in mice
Lee, W. W. L., Teo, T., Lum, F., Andiappan, A. K., Amrun, S. N., Rénia, L., Rötzschke, O., & Ng, L. F. P. (2016) · Scientific Reports · doi:10.1038/srep37603 · Cited by 18
Krackhardt, A. M., Anliker, B., Hildebrandt, M., Bachmann, M. P., Eichmüller, S. B., Nettelbeck, D. M., Renner, M., Uharek, L., Willimsky, G., Schmitt, M. W., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2119-y · Cited by 18
“With respect to antigen recognition by defined CARs, preclinical in vivo activity and safety may be investigated in selected animal models in case the target antigen provides a high homology to the target structure in humans, although minor differences in reactivity may result in unforeseen major toxicities as previou…”
BackgroundImmunologic mechanisms in RCC and allogeneic renal transplant rejection
Bedke, J., & Stenzl, A. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.59 · Cited by 17
“However, anti-CD28 antibodies have been shown to have unintended agonistic effects, resulting in cytokine release and unacceptable complications”
Ethical Issues in Translational Research
Petrini, C. (2010) · Perspectives in biology and medicine · doi:10.1353/pbm.2010.0007 · Cited by 17
“Safety is crucial, since toxicity and adverse events in man may happen at very low doses or at doses that were safe in animal models (Suntharalingam et al. 2006;Wood and Darbshire 2006).”
BackgroundBiologic immune modifiers: Trials and tribulations—are we there yet?
Ballow, M. C. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.024 · Cited by 16
Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse
González, P. A., Carreño, L. J., Céspedes, P. F., Bueno, S. M., Riedel, C. A., & Kalergis, A. M. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/450291 · Cited by 17
“However, intravenous administration of the antibody unexpectedly induced a systemic inflammatory response, known as a cytokine storm, which was severely deleterious for otherwise healthy individuals [251].”
BackgroundAn Examination of Chimpanzee Use in Human Cancer Research
Bailey, J. (2009) · Alternatives to Laboratory Animals · doi:10.1177/026119290903700410 · Cited by 17
“Multiple cytokine release syndrome ensued, leading to multiple organ failure and, in some cases, cardiovascular shock and acute respiratory distress syndrome (195) — in complete contrast to the NHP preclinical safety data.”
Dollery, C. T. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100363 · Cited by 16
Okpasuo, O. J., Olaoba, O. T., Bokolo, P., Aleke, A. S., Dare, A., Adelusi, T. I., & Jackson, C. D. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105037 · Cited by 18
van der Laan, J. W., Benson, C., Janssens, W., Bos, J., Stahl, E., Brady, J. T., Wändel‐Liminga, U., Corriol‐Rohou, S., Forster, R. P., Hartmann, A., et al. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00077-3 · Cited by 16
Advanced tissue engineering for in vitro drug safety testing
Owens, R. M. (2023) · MRS Communications · doi:10.1557/s43579-023-00421-7 · Cited by 20
“[32] In pre-clinical models, no adverse toxicity or proinflammatory effects had been observed.”
BackgroundPullen, R. H., Sassano, E. R., Agrawal, P., Escobar, J., Chehtane, M., Schanen, B. C., Drake, D. R., Luna, E., & Brennan, R. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300185 · Cited by 16
Jamal, M. E., & Shibli, F. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00136 · Cited by 16
Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation
Pilat, N., Schwarz, C. C., & Wekerle, T. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328355fc94 · Cited by 16
“TGN1412, a humanized superagonistic antihuman CD28 mAb (developed by TeGenero AG), which was tested in a clinical phase I trial in healthy volunteers, led to the development of life-threatening multiorgan failure attributable to massive cytokine release [50].”
BackgroundSingh, M., Basu, S., Camell, C. D., Couturier, J. P., Nudelman, R. J., Medina, M. Á., Rodgers, J. R., & Lewis, D. E. (2008) · European Journal of Immunology · doi:10.1002/eji.200737929 · Cited by 17
Thorpe, S. J., Stebbings, R., Findlay, L., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Cytokine · doi:10.1016/j.cyto.2013.07.009 · Cited by 15
Immunomodulating antibodies and drugs for the treatment of hematological malignancies
Houot, R., Kohrt, H. E. K., Goldstein, M. J., & Levy, R. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9274-3 · Cited by 16
“In 2006, a phase I clinical trial tested an agonistic mAb against CD28, a stimulatory receptor that is constitutively expressed on T cells, in six volunteer patients [6].”
BackgroundT-cell activation or tolerization: the Yin and Yang of bacterial superantigens
Sähr, A., Foermer, S., Hildebrand, D., & Heeg, K. M. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.01153 · Cited by 19
Regulation of Monoclonal Antibody Immunotherapy by FcγRIIB
Stopforth, R. J., Cleary, K. L. S., & Cragg, M. S. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0247-8 · Cited by 19
Liu, D., Ma, X., Liu, Y., Zhou, H., Shi, C., Wu, F. S.-Y., Jiang, J., & Hu, P. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.04.020 · Cited by 16
“It may not be right where the disease pathology and pharmacology are known to be significantly different between them ([16]).”
BackgroundIn Vivo Murine-Matured Human CD3 + Cells as a Preclinical Model for T Cell-Based Immunotherapies
Haworth, K. G., Ironside, C. M., Norgaard, Z. K., Obenza, W., Adair, J. E., & Kiem, H. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.05.004 · Cited by 15
Cytokine Storms: Systemic Disasters of Infectious Diseases
Nazinitsky, A., & Rosenthal, K. S. (2010) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0b013e3181d2ee41 · Cited by 19
Timlin, H., & Bingham, C. O. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.900536 · Cited by 17
“TGN1412, a mAb that bound and activated CD28, was developed based on animal models of efficacy in autoimmune disease, but in early stage human trials, the drug served as an acute superagonist of lymphocytes unexpectedly leading to multiorgan failure [70].”
MethodManipulation of Regulatory T-Cell Function by Immunomodulators: A Boon or a Curse?
Fort, M. M., & Narayanan, P. K. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq136 · Cited by 15
“However, in contrast to the beneficial effects demonstrated in the rat, a fully humanized human CD28SA, TGN1412, induced a life-threatening cytokine release syndrome during a first in human trial (Suntharalingam et al., 2006).”
BackgroundAzcutia, V., Bassil, R., Herter, J. M., Engelbertsen, D., Newton, G. A., Autio, A. K., Mayadas, T. N., Lichtman, A. H., Khoury, S. J., Parkos, C. A., et al. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3a1215-546rr · Cited by 17
Chen, J., Guo, X., Li, H., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i5.817 · Cited by 15
Pavlova, A., Maschan, M. A., & Ponomarev, V. (2017) · Oncohematology · doi:10.17650/1818-8346-2017-12-1-17-32 · Cited by 17
Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies
Herzyk, D. J., & Haggerty, H. G. (2018) · The AAPS Journal · doi:10.1208/s12248-017-0184-3 · Cited by 15
“TGN1412, a super co-stimulatory agonistic mAb to CD28, whose mechanism bypasses the need for antigen signaling leading to polyclonal T cell expansion, was administered to six healthy human volunteers in a first-in-human (FIH) trial (4).”
BackgroundAssessment of Cardiotoxicity With Stem Cell-based Strategies
Stoter, A. M. S., Hirt, M. N., Stenzig, J., & Weinberger, F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.08.012 · Cited by 18
Cirka, H., & Nguyen, T. (2025) · Advances in Wound Care · doi:10.1089/wound.2024.0082 · Cited by 25
The immunosuppressive mechanisms induced by sepsis and the corresponding treatment strategies
Gao, Q., Teng, Y., Zhu, L., Zhang, W., & Li, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1643194 · Cited by 27
Kamperschroer, C., Collinge, M., Heyen, J. R. R., Ji, C., O’Donnell, L. M., & Zhu, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64229-0 · Cited by 17
Li, Q., He, Y., & Pan, J. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad511 · Cited by 19
“The TGN1412 incident [6] that occurred in the UK in 2006 and the fatty acid amide hydrolase (FAAH) Phase I clinical trial incident in France in 2016 [7, 8] both resulted in catastrophic outcomes such as death and injuries.”
BackgroundAntibody-Based Immunotherapy for Malignant Glioma
Gedeon, P. C., Riccione, K. A., Fecci, P. E., & Sampson, J. H. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.06.004 · Cited by 14
Predicting cytokine storms: it's about density
Frigault, M. J., & June, C. H. (2011) · Blood · doi:10.1182/blood-2011-10-382598 · Cited by 14
From laboratory to Phase I/II cancer trials with recombinant biotherapeutics
Tolner, B., Smith, L., Hillyer, T., Bhatia, J., Beckett, P., Robson, L., Sharma, S. K., Griffin, N., Vervecken, W., Contreras, R., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.027 · Cited by 15
Using monoclonal antibodies to stimulate antitumor cellular immunity
Durrant, L. G., Pudney, V. A., & Spendlove, I. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.33 · Cited by 14
Is there a role of synovial biopsy in drug development?
Filková, M., Cope, A. P., Mant, T., & Galloway, J. B. (2016) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-016-1028-5 · Cited by 15
“[13].”
CAR-T cell and Personalized Medicine
Cruz‐Ramos, M., & García‐Foncillas, J. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-24100-1_9 · Cited by 23
Kale, S. D., Mehrkens, B., Stegman, M. M., Kastelberg, B., Carnes, H., McNeill, R. J., Rizzo, A. L., Karyala, S. V., Coutermarsh‐Ott, S. L., Fretz, J. A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01311 · Cited by 16
Stinson, J. A., Sheen, A. M., Momin, N., Hampel, J., Bernstein, R., Kamerer, R. L., Fadl-Alla, B. A., Samuelson, J., Fink, E., Fan, T. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0006 · Cited by 15
Update on Immunotherapy in Melanoma
Green, J. A., & Ariyan, C. E. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.12.010 · Cited by 15
Ex Vivo Metrics™, a preclinical tool in new drug development
Curtis, C. G., Bilyard, K. G., & Stephenson, H. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-5 · Cited by 14
“In response to this, as well as to recent, high-profile safety and toxicity issues [1,3], many companies have chosen to avoid risk by making incremental improvements to existing products rather than focusing on innovation and expansion based on exploratory research.”
Ubagai, T., Nakano, R., Nakano, A., Kamoshida, G., & Ono, Y. (2015) · Innate Immunity · doi:10.1177/1753425915605892 · Cited by 14
Ethical considerations and challenges in first-in-human research
Koonrungsesomboon, N., Laothavorn, J., & Karbwang, J. (2016) · Translational research · doi:10.1016/j.trsl.2016.05.006 · Cited by 22
Assessment of the immunogenicity of residual host cell protein impurities of OsrHSA
Abiri, N., Pang, J., Ou, J., Shi, B., Wang, X., Zhang, S., Sun, Y., & Yang, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193339 · Cited by 14
Adverse drug reactions: reducing the burden of treatment
Jordan, S. E. (2007) · Nursing Standard · doi:10.7748/ns.21.34.35.s54 · Cited by 20
Morgan, A. W., Hale, G., Rebello, P., Richards, S. J., Gooi, H. C., Waldmann, H., Emery, P., & Isaacs, J. D. (2008) · QJM · doi:10.1093/qjmed/hcn006 · Cited by 14
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.